MRK Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Merck & Co., Inc. Securities Class Action
SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
Merck’s $8 Billion Cancer Vaccine Faces First US Trial
Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.
Hosted on MSN1d
The New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks Therapeutics
For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...
MRK INVESTOR DEADLINE: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 20, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, ...
pharmaceuticalcommerce1d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
FiercePharma1d
Merck KGaA’s EMD Serono taps Selma Blair to join long-running campaign for MS drug Mavenclad
Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...
C&EN2d
Long COVID studies stymied by pharma’s lack of cooperation
Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.
BioSpace2d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
STAT2d
Pharmalittle: We’re reading about Trump tariffs on drugs, a delayed Merck vaccine court trial, and more
President Trump told reporters that tariffs on pharmaceuticals would start at "25% or higher," but did not say when they ...
BioSpace2d
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
FiercePharma2d
Amid Merck supply squeeze, ImmunityBio and Serum Institute snag FDA blessing for BCG expanded access program
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
Merck Vaccine Trial Delayed as RFK Jr. Link Creates Jury Concern
Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...